Jatenzo Pharmacokinetics (ADME): How Oral Testosterone Undecanoate Works in the Body

Why Jatenzo's Pharmacokinetics Matter Clinically

The pharmacokinetic profile of any testosterone replacement therapy determines its efficacy, dosing schedule, safety margin, and patient adherence. Jatenzo is the first FDA-approved oral testosterone undecanoate capsule in the United States, receiving approval in March 2019 under a Risk Evaluation and Mitigation Strategy (REMS) for blood pressure monitoring [1]. Its clinical relevance rests on a single pharmacokinetic innovation: lymphatic absorption that avoids the liver damage historically associated with 17-alpha-alkylated oral androgens like methyltestosterone.

The Problem With Earlier Oral Androgens

Methyltestosterone and fluoxymesterone, both 17-alpha-alkylated compounds, pass directly through the portal circulation into the liver. This first-pass exposure causes dose-dependent hepatotoxicity, including cholestatic jaundice and peliosis hepatis [2]. The Endocrine Society's 2018 clinical practice guideline specifically recommended against 17-alpha-alkylated androgens for testosterone replacement [3]. Jatenzo solved this problem by using a lipophilic undecanoate ester that is absorbed into intestinal lacteals rather than portal blood.

Clinical Significance of the Lymphatic Route

Because the drug enters systemic circulation via the thoracic duct rather than the portal vein, hepatic exposure during first pass is minimal. In the FDA's review of Jatenzo's New Drug Application, no clinically significant hepatotoxicity signals emerged in trials enrolling over 900 hypogonadal men [1]. This is a direct pharmacokinetic advantage, not just a theoretical one.

Absorption: The Lymphatic Pathway Explained

Jatenzo's absorption is its most distinctive pharmacokinetic feature. Oral testosterone undecanoate is a prodrug. The undecanoate ester makes the molecule highly lipophilic (log P > 7), which drives its partitioning into intestinal chylomicrons rather than portal venous blood [4].

Mechanism of Lymphatic Uptake

After ingestion with food, pancreatic lipase and bile salts support emulsification of the lipophilic testosterone undecanoate in the small intestine. The drug is incorporated into chylomicrons within enterocytes and secreted into intestinal lacteals. These lacteals drain into mesenteric lymph nodes, then into the thoracic duct, and finally into the left subclavian vein [4]. The entire pathway avoids the portal vein and liver. This mechanism is shared with other highly lipophilic drugs (e.g., halofantrine, probucol), but testosterone undecanoate was the first androgen to exploit it for oral delivery.

Food Effect on Absorption

Jatenzo must be taken with food. This is not optional. The FDA label specifies administration with a meal, and pharmacokinetic studies show that fasting conditions reduce testosterone exposure by approximately 40 to 50% compared to a fat-containing meal [1]. A crossover study in healthy men demonstrated that a meal containing at least 19 grams of fat produced Cmax values 2- to 3-fold higher than a low-fat meal [5]. The practical implication: patients who skip breakfast or take Jatenzo on an empty stomach will have subtherapeutic testosterone levels.

Time to Peak Concentration

Median Tmax for serum testosterone after a single dose of Jatenzo ranges from 1.5 to 6 hours, with most patients peaking around 4 to 5 hours [1]. This wide window reflects inter-individual variability in gastric emptying, meal composition, and lymphatic transit time. After repeated twice-daily dosing, the Tmax narrows as steady-state kinetics stabilize the absorption profile.

Bioavailability Considerations

Absolute oral bioavailability of testosterone undecanoate has not been formally reported by the manufacturer due to the complexity of the lymphatic route. Relative bioavailability studies comparing Jatenzo to the European formulation (Andriol Testocaps) showed that Jatenzo's self-emulsifying drug delivery system (SEDDS) produced more consistent absorption across meal types [6]. The SEDDS formulation contains a mixture of lipids and surfactants that partially pre-emulsify the drug, reducing the dependence on endogenous bile salt concentration.

Distribution: Where Testosterone Goes After Absorption

Once testosterone undecanoate enters systemic circulation via the thoracic duct, plasma esterases rapidly cleave the undecanoate ester to release free testosterone. Distribution then follows the same pathways as endogenous testosterone.

Protein Binding

Approximately 40% of circulating testosterone binds to sex hormone-binding globulin (SHBG) with high affinity (Kd ~1 nmol/L). Another 54 to 58% binds loosely to albumin. Only about 2% circulates as free, unbound testosterone [7]. The free and albumin-bound fractions together constitute "bioavailable testosterone," which is the pharmacologically active pool that enters target tissues.

Volume of Distribution

The apparent volume of distribution for testosterone is large, estimated at 1,600 to 1,800 liters in pharmacokinetic models of injectable testosterone formulations [7]. This reflects extensive tissue uptake into skeletal muscle, adipose tissue, bone marrow, brain, and reproductive organs. Specific Vd data for Jatenzo's oral formulation have not been published separately, but the distribution phase is expected to be identical once the drug reaches systemic circulation as cleaved testosterone.

Tissue Targets

Testosterone enters target cells by passive diffusion and is converted intracellularly to dihydrotestosterone (DHT) by 5-alpha-reductase (primarily type II in prostate, genital skin, and hair follicles) or to estradiol by aromatase (CYP19A1) in adipose tissue, brain, and bone [8]. Both metabolites are pharmacologically active. DHT has a 2- to 3-fold higher binding affinity for the androgen receptor than testosterone itself.

Metabolism: Ester Hydrolysis and Hepatic Biotransformation

Jatenzo undergoes two sequential metabolic phases. The first is ester cleavage. The second is standard testosterone biotransformation.

Phase 1: Ester Hydrolysis

Plasma and tissue esterases cleave the undecanoate side chain (an 11-carbon fatty acid) from the testosterone molecule. This reaction occurs rapidly, with a hydrolysis half-life estimated at 20 to 30 minutes in human plasma in vitro [4]. The released undecanoic acid enters normal fatty acid metabolism. The released testosterone is then subject to the same metabolic pathways as endogenous hormone.

Phase 2: Hepatic Oxidation and Conjugation

Testosterone is metabolized primarily by hepatic cytochrome P450 enzymes, including CYP3A4 and, to a lesser extent, CYP2C9 and CYP2C19 [9]. The major oxidative metabolites are 6-beta-hydroxytestosterone and androstenedione. Androstenedione can be further reduced to androsterone and etiocholanolone.

These phase I metabolites then undergo phase II conjugation, primarily glucuronidation by UGT2B17 and UGT2B7, and sulfation by SULT2A1 [9]. The resulting glucuronide and sulfate conjugates are water-soluble and excreted renally. A pharmacogenomic note: UGT2B17 exhibits a common deletion polymorphism (present in approximately 10% of Caucasians and up to 70% of East Asian populations) that significantly alters testosterone glucuronide clearance [10].

DHT and Estradiol Formation

Because Jatenzo delivers testosterone (after ester cleavage), serum DHT levels increase proportionally. In the key trial by Swerdloff et al. (2020), the DHT-to-testosterone ratio remained within physiological range for most patients, although individual variability was notable [11]. Estradiol levels also rose modestly, consistent with aromatization in peripheral tissues. The clinical relevance: physicians monitoring Jatenzo therapy should track both DHT (for androgenic side effects) and estradiol (for gynecomastia risk) alongside total and free testosterone.

Drug-Drug Interaction Potential

Because CYP3A4 is involved in testosterone metabolism, strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) may increase serum testosterone concentrations, while strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) may decrease them [1]. The FDA label recommends monitoring testosterone levels when Jatenzo is co-administered with strong CYP3A4 modulators. Insulin and oral hypoglycemic agents may also require dose adjustment, as testosterone can improve insulin sensitivity and lower blood glucose in hypogonadal men with type 2 diabetes [3].

Elimination: Half-Life and Excretion

Testosterone itself has a short circulating half-life. But the pharmacokinetic behavior of Jatenzo is more nuanced because absorption from the lymphatic system creates a prolonged input phase.

Apparent Terminal Half-Life

The terminal elimination half-life of testosterone in serum is approximately 10 to 100 minutes, depending on the assay method and compartmental model used [7]. For Jatenzo, the apparent half-life is longer (roughly 5 to 6 hours based on the serum concentration-time curve) because the slow lymphatic absorption overlaps with elimination, creating a flip-flop kinetic pattern [1]. This is why twice-daily dosing maintains serum testosterone within the eugonadal range (300 to 1,100 ng/dL) in most patients.

Excretion Routes

Approximately 90% of a testosterone dose is excreted in urine as glucuronide and sulfate conjugates. About 6% is eliminated in feces, primarily as unconjugated metabolites undergoing enterohepatic recirculation [7]. Renal impairment does not significantly alter Jatenzo's pharmacokinetics in mild to moderate cases, though the drug has not been studied in severe renal impairment (eGFR <30 mL/min) [1].

Steady-State Kinetics

At the recommended starting dose of 237 mg twice daily, Jatenzo reaches steady-state serum testosterone concentrations within approximately 7 days [1]. The average steady-state Cavg ranges from 300 to 500 ng/dL in clinical trial populations. Dose titration (158 mg, 198 mg, 237 mg, or 316 mg twice daily) is guided by serum testosterone measured 3 to 5 hours after the morning dose, targeting a Cavg between 300 and 1,050 ng/dL [11].

Key Clinical Pharmacokinetic Data

The registration trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and measured pharmacokinetic endpoints over 12 months [11]. This study remains the primary source of human PK data for Jatenzo.

Key Findings From the Swerdloff Trial

At the end of the dose-titration phase (day 90), 87% of patients achieved a serum testosterone Cavg within the normal male range of 300 to 1,100 ng/dL [11]. The maximum observed concentration (Cmax) exceeded 1,500 ng/dL in fewer than 5% of patients at any dose level, suggesting a low risk of supraphysiologic spikes compared to some injectable testosterone formulations. The Cmin (trough before the next dose) averaged 280 to 350 ng/dL at steady state, which is above the hypogonadal threshold of 300 ng/dL for most patients.

Dr. Ronald Swerdloff, lead investigator and endocrinologist at the Lundquist Institute, stated: "The oral route of testosterone delivery through the lymphatic system represents a meaningful pharmacokinetic advance, offering consistent serum levels without the hepatotoxicity seen with older oral androgens" [11].

Comparison to Intramuscular Testosterone

Injectable testosterone cypionate (100 to 200 mg every 1 to 2 weeks) produces serum testosterone peaks of 1,200 to 1,500 ng/dL within 24 to 48 hours, followed by a decline to trough levels of 200 to 400 ng/dL before the next injection [3]. This sawtooth pattern contrasts with Jatenzo's flatter pharmacokinetic profile, where the twice-daily dosing keeps the peak-to-trough ratio much smaller. As the Endocrine Society guidelines note, "the choice of testosterone formulation should consider pharmacokinetic profile, patient preference, and cost" [3].

Special Populations and PK Variability

Obesity and BMI Effects

Body mass index affects testosterone pharmacokinetics in two ways. First, higher BMI is associated with increased aromatase activity in adipose tissue, converting more testosterone to estradiol. Second, the volume of distribution expands with body fat. In a subgroup analysis of the Swerdloff trial, men with BMI > 35 kg/m² required higher Jatenzo doses (316 mg twice daily) to achieve target Cavg more frequently than leaner men [11]. Clinicians should anticipate dose titration upward in obese patients.

Hepatic Impairment

Jatenzo has not been studied in men with moderate or severe hepatic impairment (Child-Pugh B or C). Because the drug bypasses first-pass hepatic metabolism, mild hepatic impairment is unlikely to affect absorption. But downstream testosterone metabolism does depend on hepatic CYP enzymes, so clearance could be reduced in cirrhosis [1]. The FDA label advises caution.

Age-Related Changes

Older men (>65 years) were included in the key trial but not analyzed as a separate pharmacokinetic subgroup. SHBG concentrations increase with age at approximately 1.2% per year after age 40, which would decrease the free testosterone fraction at any given total testosterone level [3]. Dose adjustments based on free testosterone measurement may be appropriate in older patients, though no specific geriatric dosing guidance exists in the current label.

Pharmacokinetic Monitoring in Clinical Practice

Serum testosterone should be measured 3 to 5 hours after the morning dose (coinciding with the Tmax window) at baseline, at 1 month, and after any dose change [1]. The goal is a Cavg of 300 to 1,050 ng/dL. If the level exceeds 1,050 ng/dL, reduce the dose by one step. If below 300 ng/dL, increase by one step or reassess adherence and meal co-ingestion.

Blood pressure monitoring is required under the REMS program: measure at baseline, at monthly visits for the first 6 months, and periodically thereafter [1]. In the key trial, mean systolic blood pressure increased by 3 to 5 mmHg in Jatenzo-treated patients versus placebo, with hypertension-related discontinuation occurring in approximately 5% of participants [11]. Hematocrit should be checked at 3 and 6 months, then annually, because all testosterone formulations can stimulate erythropoiesis and increase polycythemia risk [3].

Confirm timing of the last dose, meal composition, and sample draw time with every lab result. A fasting sample or a sample drawn 8 hours post-dose will yield a misleadingly low testosterone concentration and may trigger unnecessary dose escalation.